- Home
- AWH vs INDP Comparison
AWH vs INDP Comparison
Compare AWH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- INDP
- Stock Information
- Founded
- AWH 1993
- INDP 2000
- Country
- AWH United States
- INDP United States
- Employees
- AWH N/A
- INDP N/A
- Industry
- AWH Medical/Dental Instruments
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- AWH Health Care
- INDP Health Care
- Exchange
- AWH Nasdaq
- INDP Nasdaq
- Market Cap
- AWH 10.5M
- INDP 10.2M
- IPO Year
- AWH N/A
- INDP N/A
- Fundamental
- Price
- AWH $0.50
- INDP $0.84
- Analyst Decision
- AWH Buy
- INDP Strong Buy
- Analyst Count
- AWH 2
- INDP 2
- Target Price
- AWH $4.40
- INDP $8.50
- AVG Volume (30 Days)
- AWH 100.3K
- INDP 25.3K
- Earning Date
- AWH 11-14-2024
- INDP 03-12-2025
- Dividend Yield
- AWH N/A
- INDP N/A
- EPS Growth
- AWH N/A
- INDP N/A
- EPS
- AWH N/A
- INDP N/A
- Revenue
- AWH $8,963,000.00
- INDP N/A
- Revenue This Year
- AWH $11.87
- INDP N/A
- Revenue Next Year
- AWH $79.10
- INDP N/A
- P/E Ratio
- AWH N/A
- INDP N/A
- Revenue Growth
- AWH N/A
- INDP N/A
- 52 Week Low
- AWH $0.38
- INDP $0.81
- 52 Week High
- AWH $5.65
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- AWH 27.14
- INDP 39.07
- Support Level
- AWH $0.38
- INDP $0.86
- Resistance Level
- AWH $0.79
- INDP $1.06
- Average True Range (ATR)
- AWH 0.07
- INDP 0.08
- MACD
- AWH -0.02
- INDP 0.00
- Stochastic Oscillator
- AWH 27.91
- INDP 12.80
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.